Table 1 Financing modalities characteristics
Financing modalities | Nomenclature reimbursment codes | Reference laboratories (RLs) | Conventions with foreign laboratories |
|---|---|---|---|
Type of medical analyses | Analyses of clinical pathology | ||
Analyses’ availability | Available in Belgium | Not available in Belgium | |
Annual volume | High | Moderate to low | Low |
Laboratories who can benefit from the financing | All Belgian laboratories of clinical pathology | Only Belgian laboratories of clinical pathology recognized as RLs | Specific foreign laboratories of clinical pathology |
Laboratories’ selection procedure | None | Belgian call for application By Sciensano Every 5 years | By the RDWG of the BCCP and Sciensano Every year |
Components of the financing | Performance of the analysis | Analytical costs Accreditation Quality controls Specific administrative costs | Analytical costs Shipment costs |
Financing source | INAMI-RIZIV (through a budget envelop specifically dedicated to the Action 1 of the Belgian plan for rare diseases) | ||
Follow-up of laboratories’ activities and quality of the analyses | By the RDWG of the BCCP and Sciensano | ||
Annual evaluation of the necessary budget | By Sciensano and the INAMI-RIZIV Insurance Committee | ||